
Skygene Pharmaceutical Private Limited
Founded in 2013 and headquartered in Delhi, India.
Founded in 2013 and headquartered in Delhi, India.
East Delhi, Delhi, India
+91-XXXXXXXXXX
U51397DL2013PTC257862
257862
Private Limited Indian Non-Government Company
16 Sep 2013
30 Sep 2015
31 Mar 2015
Unlisted
Roc-Delhi
Name | Designation | Appointment Date | Status |
---|---|---|---|
Shailendra Pal ![]() | Director | 16-Sep-2013 | Current |
Archana Yadav ![]() | Director | 01-Jan-2016 | Current |
Enhance accessibility to Skygene Pharmaceutical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets | |||||||
Profit or Loss | |||||||
Net Worth | |||||||
EBITDA |
Unlock access to Skygene Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Skygene Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Skygene Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skygene Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Archana Yadav was appointed as a Director was appointed as a Director on 01 Jan 2016 & has been associated with this company since 9 years 4 months .
Skygene Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2015 as per latest MCA records.
Skygene Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2015 with RoC-Delhi.
Shailendra Bahadur Pal was appointed as a Director was appointed as a Director on 16 Sep 2013 & has been associated with this company since 11 years 7 months .
Skygene Pharmaceutical Private Limited was registered on 16 Sep 2013 with RoC-Delhi & aged 11 years 7 months as per MCA records.
Skygene Pharmaceutical Private Limited was incorporated on 16 Sep 2013.
The authorized share capital of Skygene Pharmaceutical Private Limited is ₹ 0.10 M and paid-up capital is ₹ 0.10 M.
Currently 2 directors are associated with Skygene Pharmaceutical Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Skygene Pharmaceutical Private Limited is C-7 First Floor, Madhu Vihar Sai Chowk I.P Extention, Delhi East Delhi, India, 110092.
The corporate identification number (CIN) of Skygene Pharmaceutical Private Limited is U51397DL2013PTC257862 and the company number is 257862 as per Ministry of Corporate Affairs (MCA).
The most recent Balance Sheet for Skygene Pharmaceutical Private Limited was filed with the ROC on 31 Mar 2015.
Search company & director profiles for free and gain access to critical business data.